Compare Crispr Therapeutics AG (CRSP) vs Tripadvisor Inc Common Stock (TRIP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Tripadvisor Inc Common Stock — how do they compare? Crispr Therapeutics AG trades at $50.61 (market cap $4.97B), while Tripadvisor Inc Common Stock trades at $14.42 (market cap $1.63B). The key difference: Crispr Therapeutics AG is far larger — about 3× Tripadvisor Inc Common Stock's market cap, and Tripadvisor Inc Common Stock is trading nearer its 52-week high, Crispr Therapeutics AG nearer its low. Which is the better fit depends on your goals.
| CRSP | TRIP | |
|---|---|---|
Market Cap | $4.97B | $1.63B |
Sector | Health | Consumer Cyclical |
52-Week High | $76.78 | $19.14 |
52-Week Low | $44.34 | $9.24 |
Enterprise Value | $3.32B | $1.75B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRSP trades at $50.63, down 5.1% over 24 hours, amid a bearish technical signal. The company shows deep losses with a net income margin of -56,853.4% in 2025 and negative cash flow from operations. However, analyst consensus remains optimistic with a $74.50 price target, and recent news highlights FDA approval for Casgevy, expanding its gene therapy market.
The outlook hinges on commercial execution of Casgevy and pipeline progress, offering high growth potential in gene editing. Key risks include sustained cash burn, competitive pressures, and regulatory hurdles. Despite current financial challenges, strong analyst buy ratings suggest confidence in long-term value.
Tripadvisor (TRIP) trades at $14.40, up 3.0% today, with technical indicators showing bullish momentum. The company reported mixed Q2 2026 earnings, missing expectations in two of the last three quarters. Recent news highlights the $700 million sale of TheFork to American Express, which may provide capital flexibility. Revenue grew to $1.89 billion in 2025, though net margins remain thin at 0.99%. Analyst consensus is mixed with 60.7% hold ratings and a $13.87 price target slightly below current levels.
The outlook is cautious due to competitive pressures and inconsistent earnings, but the stock shows technical strength. Opportunities include potential benefits from the TheFork sale and travel sector recovery. Key risks are macroeconomic headwinds and execution challenges in core segments. Investors should weigh solid cash flow against high P/E valuation and analyst skepticism for near-term performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Tripadvisor Inc Common Stock
TripAdvisor is the world's leading travel metasearch company. The website offers 1 billion reviews and information on about 8 million accommodations, restaurants, experiences, airlines, and cruises. In 2021, 74% of revenue came from the company's core segment, which includes hotel revenue generated through advertising on its metasearch platform. Viator, its experiences brand, was 20% of sales in 2021, and TheFork, its dining brand, represented 9% of revenue (about 3% of sales were intersegment, which are eliminated from consolidated revenue).
Read more on TRIP →
